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Objective: The objective of this study was to compare the results of aortic valve-
sparing reimplantation and aortic root replacement with mechanical valve conduits
in patients with Marfan syndrome undergoing operation for aortic root aneurysms.
Patients and Methods: Between March 1979 and April 2002, 119 patients with
clinical evidence of Marfan syndrome underwent composite graft replacement with
mechanical valve conduits (n  74) or aortic valve-sparing reimplantation accord-
ing to David (n  45). The underlying causes were aortic dissection type A (43
patients) and aneurysms (76 patients).
Results: Patients undergoing aortic valve reimplantation were younger compared
with patients undergoing composite grafting (28 vs 35 years, P  .002) and had
longer intraoperative aortic crossclamp times (125 vs 78 minutes, P  .0001) and
extracorporeal circulation times (162 vs 124 minutes, P  .0001). Early postoper-
ative mortality was 6.8% (n  5) in patients undergoing composite grafting and 0%
in patients undergoing aortic valve reimplantation (P  .15). Mean follow-up was
30 months for patients undergoing aortic valve reimplantation and 114 months for
patients undergoing composite grafting. Freedom from reoperation and death after
5 years postoperatively was 92% and 89% in patients undergoing composite grafting
and 84% and 96% in patients undergoing aortic valve reimplantation (P  .31; P 
.54), respectively. Thromboembolic complications or late postoperative bleeding
occurred in 17 patients undergoing composite grafting, and an early postoperative
event occurred in 1 patient undergoing aortic valve reimplantation.
Conclusions: The results of aortic valve reimplantation and composite grafting of
the aortic valve and ascending aorta with mechanical valve conduits are similar with
regard to early and mid-term postoperative mortality and to the incidence of late
reoperations in patients with Marfan syndrome. The low risk of thromboembolic or
bleeding complications favors aortic valve reimplantation in these patients.
The life expectancy of patients with Marfan syndrome has increaseddramatically in the last 30 years.1,2 The introduction of the Bentallprocedure and its variants into clinical practice had a major impacton this positive development.3 Today, implantation of a valvedconduit for aortic root replacement is the gold standard for patientswith Marfan syndrome presenting with aneurysms of the aortic root.4
Although early and late postoperative outcomes of this procedure have been excel-
lent, a significant proportion of patients with mechanical valve substitutes experi-
ence complications related to long-term anticoagulation with phenprocoumon.5 This
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fact and the generally young age of patients with Marfan
syndrome undergoing surgery of the aortic root render bi-
ologic or even valve-sparing operative concepts attractive.
However, there is a reluctance among surgeons with regard
to preservation of the aortic valve in patients with Marfan
syndrome because leaflets carrying a structural fibrillin-1
defect may not be stable enough for a long time, regardless
of the type of valve reconstruction.6
On the other hand, there is increasing evidence that
valve-sparing operations, such as the aortic root remodeling
technique according to Yacoub or the reimplantation tech-
nique according to David, can be applied with good func-
tional long-term results in patients with Marfan syndrome
too.7-9 This observation and the surprisingly long freedom
from valve failure of up to 29 years that has been reported
after 4 valve-sparing aortic root operations by Senning are
good reasons to contest the restraints in this regard.4
Since 1993, we have used the aortic valve reimplantation
technique according to David and have expanded the indi-
cations for this operation from acquired root pathologies to
patients with Marfan syndrome with aneurysms of the aortic
root.10 This report summarizes our experience with the
reimplantation technique in 45 patients with Marfan syn-
drome in comparison with a nonmatched cohort of patients
with Marfan syndrome who underwent aortic root replace-
ment with mechanical valve conduits.
Materials and Methods
From March 1979 to April 2002, 132 patients with Marfan syn-
drome according to the Gent criteria underwent operation on the
aortic root.11 Thirteen patients underwent aortic root replacement
with a bioconduit (5 patients), resuspension of 1 or more aortic
valve commissures and ascending aortic replacement (5 patients),
aortic root reconstruction with gelatin resorcin formaldehyde glue
and ascending aortic replacement (2 patients), or aortic root re-
modeling according to Yacoub (1 patient). In the other 119 pa-
tients, 45 underwent aortic valve reimplantation according to the
method described by David and 74 underwent aortic root replace-
ment with a mechanical valve conduit.3,8 Patients from the latter 2
cohorts form the basis of the subsequent analysis. The mean age of
patients was 32 years (range 8-67 years). Operative procedures
were performed electively in 99 cases. In 20 cases, however,
patients had to undergo emergency surgery for acute aortic dis-
section type A. In most patients with Marfan syndrome undergoing
operations between 1979 and 1993, aortic root replacement was
performed with a composite graft of the aortic valve and ascending
aorta. In 1993, aortic valve reimplantation was introduced in our
institution. Since then, the number of patients undergoing this kind
of valve-sparing operation has increased, whereas fewer and fewer
patients have undergone combined replacement of the ascending
aorta and aortic valve.
Table 1 summarizes the preoperative characteristics of patients
who underwent aortic valve reimplantation or aortic root replace-
ment with a mechanical valve conduit. Table 2 shows the operative
data. Patients were followed up at annual intervals. Doppler echo-
cardiography was performed in patients with aortic valve reim-
plantation. In addition, all patients with aortic dissection or sub-
critical aortic dilatation were reinvestigated serially by computed
tomography. The mean follow-up was 30  27 months (1-95
months) for patients who underwent aortic valve reimplantation
and 114  63 months (2-249 months) for patients who underwent
composite graft replacement of the aortic valve and ascending
aorta. None of these patients were lost to follow-up. Infectious,
thromboembolic, and bleeding complications were recorded as
recommended by the guidelines of the American Association for
Thoracic Surgery and Society of Thoracic Surgeons.12
Statistical Analysis
Continuous variables are expressed as mean  SD. All data
analyses were performed with SPSS 11.0 for Windows (SPSS,
Chicago, Ill). Kaplan-Meier analysis was used for the evaluation of
time-related variables, and the log-rank test was applied. The
Mann-Whitney test was used for variables that were not normally
TABLE 1. Preoperative characteristics of the patients who





Number of patients 45 74
Mean age (y) (mean  SD) 28 12 35 11 .002
Sex
Male 29 (64) 49 (66)
Female 16 (36) 25 (34)
Aneurysm 41 (91) 35 (47) .0001
Type A aortic dissection
Acute 3 (7) 17 (23)
Chronic 1 (2) 22 (30)
Associated pathology
Bicuspid aortic valve 1 (2) 3 (4)
Coronary artery disease 1 (2) 0
Mitral insufficiency 8 (18) 5 (7)
Previous cardiac surgery 0 9 (12) .013
*Percentages are shown in parentheses.






(n  74) P value
Extracorporeal circulation time 162 34 124 45 .0001
Aortic crossclamp time 125 29 78 26 .0001
Additional procedures
Mitral valve repair 8 (18) 0 .0001
Mitral valve replacement 0 5 (7) .15
Proximal aortic arch replacement 4 (9) 15 (20) .12
Total aortic arch replacement 0 4 (5) .29
Coronary artery bypass 1 (2) 4 (5) .64
ASD closure 1 (2) 0 .05
Funnel chest reconstruction 2 (4) 1 (1) .55
ASD, Atrial septal defect.
*Percentages are shown in parentheses.
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distributed. The Student t test for independent variables was used
to test normally distributed variables between the composite and
aortic valve reimplantation groups. Analysis of contingency tables
was performed by Fisher’s exact test or the 2 test.
Results
Hospital Mortality and Early and Late Postoperative
Morbidity
Five patients (6.8%) died in hospital after aortic root re-
placement, whereas no patients died early after aortic valve
reimplantation. Of these fatalities, the causes were acute
type A aortic dissection in 2 patients, aneurysms in 2
patients, and chronic type A aortic dissection in 1 patient.
Three patients died of low cardiac output after double
reexploration of the mediastinum for bleeding. The other
causes of early death were sepsis in 1 patient and stroke in
1 patient who underwent additional subtotal replacement of
the aortic arch.
Altogether, 10 patients required reexploration of the me-
diastinum for bleeding (2 in the valve reimplantation group
and 8 in the root replacement group).
There was no perioperative stroke, myocardial infarc-
tion, or infection in the reimplantation group. In the root
replacement group, 2 patients had nonfatal strokes, 2 pa-
tients had reversible ischemic neurologic deficits, and 1
patient had a transient ischemic attack. None of these pa-
tients underwent additional mitral valve surgery. The anti-
coagulant status reported closest to the respective events
ranged between 2.5 and 3.5 international normalized ratio in
all patients.
The length of hospital stay was 15  9 days in the
reimplantation cohort and 20  18 days in the aortic root
replacement cohort (P  .08).
There were 12 patients who had bleeding events in the
root replacement group during further follow-up (3 with
intracerebral bleeding, 3 with retinal bleeding, 3 with gas-
trointestinal bleeding, and 3 with severe epistaxis). No such
episodes were reported in the reimplantation group.
Altogether, there were 17 of 69 survivors (24%) in the
root replacement group with a mechanical valve substitute
who experienced bleeding episodes or thromboembolic
events during their follow-up. In the reimplantation group,
however, only 1 patient had a transient ischemic attack early
postoperatively.
Reoperations and Late Results
Reoperation on the aortic valve was performed in 4 patients
(9%) after valve reimplantation. Technical problems during
primary repair caused severe aortic valve incompetence 20
days postoperatively in 1 patient. Progressive aortic insuf-
ficiency (AI) during the first postoperative year occurred in
2 patients. At reoperation, cusp prolapse as the result of
inadequate technique at the primary repair was identified as
the cause of valve failure. Both patients demonstrated less
than optimal cusp coaptation with aortic regurgitation
greater than grade 1 in the early postoperative period. One
patient received a prophylactic aortic valve replacement for
AI grade II during aortic arch replacement 41 months after
the primary repair. Preoperative echocardiography had re-
vealed mild cusp prolapse beyond the inferior edge of the
vascular graft. In all patients, valve replacement was per-
formed within the Dacron prosthesis using mechanical pros-
theses. All patients recovered promptly from the second
operation.
Seven patients (9%) underwent cardiac reoperations after
root replacement; indications were related to the composite
graft in 6 of these patients. Two patients had prosthetic
valve endocarditis. Other indications were persistent perfu-
sion of the perigraft space in 1 patient, malfunction of the
prosthetic heart valve in 1 patient, perforation near a coro-
nary reimplantation site in 1 patient, and a relevant subpros-
thetic ventricular septal defect in 1 patient. One patient
underwent heart transplantation for progressive cardiomy-
opathy late after root replacement. Two of the 7 patients in
this subcohort died early postoperatively. Both patients un-
derwent reoperation for prosthetic valve endocarditis. In 1
of these patients, the conduit was replaced by another com-
posite graft, whereas the other patient underwent partial
replacement of the ascending aortic prosthesis together with
direct closure of a paravalvular leak. The former patient
died as a sequel of early postoperative resuscitation and
subsequent stroke, and the latter patient died of septic com-
plications 10 days postoperatively. The other 5 patients are
alive.
Figure 1 shows freedom from reoperation in both groups
of patients; at 5 years it was 84%  8% for patients who
underwent aortic valve reimplantation and 92%  3% for
patients who underwent aortic root replacement (P .31).
In the reimplantation group, 3 patients died late postop-
eratively. In 1 patient, the cause of death was rupture of the
native downstream aorta 5 years after primary repair. The 2
other patients died 5 and 6 years postoperatively of un-
known reasons, therefore according to the respective guide-
lines, cardiac reasons.12 One patient died 4 years after
mechanical aortic valve replacement as a reoperation for
valve reimplantation. The cause of death was therefore
unrelated to valve failure after reimplantation.
Figure 2 shows the survival in both groups of patients.
Survival at 5 years was 96%  4% for patients who under-
went aortic valve reimplantation and 89% 4% for patients
who underwent aortic root replacement (P  .54).
Figure 3 summarizes the results from the preoperative,
early postoperative, and most recent Doppler echocardio-
graphic study in patients who underwent aortic valve reim-
plantation. At the last visit, 23 patients showed no AI, 13
patients showed trivial AI, and 1 patient showed moderate
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to severe AI, who is presently not willing to undergo reop-
eration because of the lack of symptoms.
After aortic root replacement, 23 of the 69 surviving
patients (33%) underwent 1 or more separate reoperations at
the downstream aorta for progressive dilatation or rupture.
Among these 23 patients, 4 died early after emergency
reoperations that were performed for imminent free rupture
or acute malperfusion. One patient in this subcohort died 10
years after descending aortic replacement for unknown reason.
After aortic valve reimplantation, 3 of the 45 surviving
patients (6%) underwent downstream aortic reoperations.
The indications were dilatation of a chronically dissected
aortic arch, dilatation of a nondissected arch, and a second-
ary subacute type B aortic dissection. All patients who
underwent reoperation were alive at the end of follow-up.
Discussion
There is an ongoing skepticism whether aortic valve-sparing
procedures in patients with Marfan syndrome are justified in
view of the proven microfibrillar abnormality within the
aortic valve leaflets.6 Ten to 15 years ago, we and others put
aside these concerns and decided to apply new and prom-
ising aortic valve-preserving concepts not only to patients
with acquired diseases of the aortic root but also to patients
with Marfan syndrome.7,8,10,13-15 We reviewed 45 patients
meeting the Gent criteria of this disorder who underwent the
classic David procedure for aneurysms of the aortic root at
a mean follow-up of 30 months (range 1-94 months). Three
results emerged from our study comparing our experience
with this operation with the respective gold standard of
composite grafting of the aortic valve and ascending aorta:
(1) Hospital mortality, mid-term survival, and incidence of
reoperation are comparable among patients undergoing op-
eration with either of the 2 procedures. (2) No late throm-
boembolic and bleeding complications were observed in
patients with aortic valve reimplantation (unlike patients
with mechanical aortic valves). (3) Once initial repair was
satisfactory, no late deterioration of valve function was
observed after aortic valve reimplantation. Therefore, we
conclude that aortic valve reimplantation according to
David is favorable for patients with Marfan syndrome when
compared with root replacement: Long-term anticoagula-
tion is not required, and the reimplanted valves have per-
formed well during the follow-up period that has accumu-
lated so far.
According to a multicenter review by Gott and col-
leagues,4 elective repair of the aortic root in patients with
Marfan syndrome carries a perioperative mortality risk of
Figure 1. Freedom from reoperation in patients with Marfan syndrome who underwent aortic valve-sparing surgery
by valve reimplantation according to David or root replacement by mechanical valved conduit.
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Figure 2. Survival of patients with Marfan syndrome who underwent aortic valve-sparing surgery by valve
reimplantation according to David or root replacement by mechanical valved conduit.
Figure 3. Grade of AI preoperatively, early postoperatively, and at last visit in patients with Marfan syndrome
undergoing aortic valve-sparing surgery by valve reimplantation according to David. Absolute numbers of patients
are given (n pts). AI, Aortic insufficiency.
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1.5%. The cumulative survival in that collective series was
85% at 5 years. These results were obtained because aortic
root replacement by composite grafting of the aortic valve
and ascending aorta has proven to be a straightforward and
safe procedure.16
The zero early postoperative mortality we obtained with
the David procedure can well compete in this regard even
though the aortic crossclamp and extracorporeal circulation
times were longer when compared with composite grafting.
This result is in accordance with the early mortality rates for
elective patients reported by David’s group and the early
results of the remodeling procedure according to Yacoub.7,9
Survival and mid-term postoperative outcome with this
technique have been satisfactory so far, with 3 patients who
died of reasons that were not attributable to valve reimplan-
tation. The cumulative survival measures 96% at 5 years,
which is comparative to results of root replacement and
other series of patients with valve-preserving proce-
dures.7,9,16
The most important adverse effect of valve repair re-
mains valve failure. Early in our experience with valve
reimplantation, 4 patients had to undergo reoperation for
technical reasons. A detailed analysis of the intraoperative
echocardiographic findings in 3 of these patients indicated
that resuspension of the commissures was too low, thereby
leading to cusp prolapse. We thus believe that radical dis-
section of the aortic root and adequate height of resuspen-
sion of the commissures are important to avoid early valve
failure.10 It remains to be determined to what extent the
structural fibrillin-1 defect can affect the stability and du-
rability of the cusps after valve reimplantation. So far, we
have no evidence (from echocardiography during follow-up
or direct inspection of explanted valves) that obvious de-
generative changes in the cusps were possibly attributable to
contact with the prosthetic vascular graft. In our opinion,
both aspects together with the more radical support of the
diseased aortic wall and the routine annular stabilization are
good reasons to continue to use David and Feindel’s8 orig-
inal technique (David I operation) in patients with Marfan
syndrome. This applies to patients with normal cusps, which
are generally found in root aneurysms smaller than 55 mm.
Valves with dilated cusps and multiple stress fenestrations,
as typically seen in larger root aneurysms, should be re-
placed.9 It is conceivable, however, that the lack of sinuses
of Valsalva still predisposes to leaflet damage, which could
unmask only during further follow-up. This concern has led
to modifications of the classic David I operation (David IV
or V) and the clinical introduction of vascular prosthesis
incorporating artificial sinuses of Valsalva.17-19
The 2 study groups (valve reimplantation and root re-
placement with a mechanical aortic valve prosthesis) had a
number of different perioperative variables (Table 1). One
of the reasons why patients who underwent valve-sparing
operations were younger when compared with patients who
received a conduit probably resides in the more recent
tendency to operate on root aneurysms at smaller diameters
(4.5-5 cm) than 20 years ago in patients with Marfan syn-
drome. During recent years, we have tried to preserve the
aortic valve in acute aortic dissection type A too. We
believe there are 2 reasons why the proportion of patients
with nondissecting aneurysms was still larger in patients
with preserved aortic valves than in patients with replaced
valves when looking at the whole study period: (1) In-
creased alertness among physicians with regard to the pos-
sible complications of Marfan syndrome may have contrib-
uted to the fact that fewer patients with Marfan syndrome
have presented with type A aortic dissection during recent
years. This may explain why only 5 patients had to undergo
operation for this diagnosis during the last 7 years of the
study period when compared with the 38 patients during the
first 16 years. (2) The David operation was introduced into
our clinical practice only during the last 9 years of the
approximately 23-year study period. Therefore, the statisti-
cal impact of the small number of patients with aortic
dissection type A who had the chance to undergo valve
reimplantation is relatively small, even though this opera-
tion was performed in all 5 patients who underwent opera-
tions since 1995 except for 1 patient with severely damaged
leaflets.
No redo cases are documented in the cohort with valve
reimplantation, whereas 12% of patients in the replacement
group had undergone previous cardiac surgery. This finding
probably reflects a surgical prevalence to accept the longer
crossclamp times of aortic valve-preserving surgery in pri-
mary procedures rather than in redo interventions.
Another difference between the cohorts was the treat-
ment of concomitant mitral valve insufficiency: There were
no mitral valve replacements in the reimplantation group,
whereas there were no mitral valve repairs in the root
replacement group. With regard to the necessity of long-
term anticoagulation, this finding reflects the efforts to re-
pair not only the aortic valve but also the mitral valve
whenever indicated.
In addition to these variables, the different length of
follow-up in both cohorts certainly limits their statistical
comparability. On the other hand, it is apparent that there
were virtually no postoperative valve-related events in the
reimplantation group. In contrast, 7.2% of the survivors of
aortic root replacement with a mechanical aortic valve sub-
stitute have had thromboembolic complications, and 17.4%
of patients have had bleeding episodes. Although other
causes for these complications are conceivable, these data
well reflect the incidence of the adverse events that have
been attributed to long-term phenprocoumon medication
after mechanical valve replacement.5 Furthermore, the risk
for dissection or dilatation of downstream aortic segments
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with the need for vascular reoperations renders patient man-
agement more difficult when long-term anticoagulation is
necessary. Considering these aspects and in view of the
presented data, we favor this valve-preserving operation in
patients with Marfan syndrome, provided the valve cusps
appear normal. However, only true long-term results will
clarify its definite value in these patients.
We thank C. Abraham, PhD, our consultant statistician, for
biostatistical review of the study.
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Discussion
Dr Tirone E. David (Toronto, Ontario, Canada). It pleases me
to know that Professor Borst introduced this operation in Hannover
almost a decade ago and that you and your associates continue to
perform it. I think it is a good operation for patients with Marfan
syndrome. Having said that, considering the results that you have
had, I would be reluctant to offer it to new patients. The patients
who had replacement of the aortic root were older and sicker, had
more aortic dissections, and had many more transverse aortic arch
replacements, and yet at 5 years the survival was the same. The
risk of reoperation in the valve-sparing group was higher than in
the aortic root replacement group. My explanation for that is not
because valve sparing is a bad operation, but rather because of its
learning curve.
I have been performing this operation for some 15 years, and I
still find it a difficult operation to teach—not the technical aspects
of reimplanting the aortic valve into a tube but the operative
judgment of whether to save or replace an aortic valve and to select
the size of the graft for the reimplantation. How did you choose the
size of the graft? What guidelines do you use in the operating room
to pick a graft of 34 or 26 mm?
Second, what do you do for the elongated cusps? Invariably if
a patient has an aortic root aneurysm, the cusps won’t be entirely
normal. Thus, the principles of functional anatomy of the aortic
valve are not easily applicable in patients with aortic root aneu-
rysm. In other words, it has been my experience that the cusps are
often elongated, particularly the noncoronary cusp. If you take a
graft of a given size, the cusps may prolapse at the end of the
operation. Do you repair the cusps? Do you shorten them?
Finally, isn’t the creation of the neo-aortic sinus important for
the function of the aortic valve? There is an increased amount of
evidence suggesting that the velocity of closure of the aortic cusps
decreases when neo-aortic sinuses are created.
Dr Karck. I am aware that you have developed a specific
formula to calculate the optimum size of the tube graft to use. This
is a difficult formula for us, and reviewing our data, it turns out that
the vast majority of patients, including patients with Marfan syn-
drome, received a 28-mm prosthesis if male and a 26-mm pros-
thesis if female. The results we obtained, even though I understand
the theoretical point, support the selection of these tube graft sizes.
Few patients with exceptionally wide annuli had tube grafts with
wider diameters.
Dr David. I’m sorry, you don’t have a criterion for selecting 26
or 28? It is random?
Dr Karck. No, we measure, but this resulted in 28-mm or
26-mm tube grafts for the majority of patients with Marfan syn-
drome.
With regard to cusp elongation, we carefully assess the aortic
valve, particularly in the area of the commissures. If there are
stress fenestrations, we replace this valve instead of trying to
reconstruct it. Commonly we see these stress fenestrations in
patients who have a very wide annulus. I missed the third question.
Dr David. The need to create neo-aortic sinuses as opposed to
a straight tube.
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Dr Karck. There are some data on the importance of sinus
function. From the work of Dr Leyh, who analyzed this aspect
between the Yacoub operation and the David operation compara-
tively, we learned that the lack of sinus function has not affected
the clinical outcome so far. In other words, with the follow-up we
have accumulated so far, we do not see deterioration of the cusps
or any disadvantages that may be attributable to the loss of sinus
function.
Dr Gerald M. Lawrie (Houston, Tex). I enjoyed this beauti-
fully presented article. I wanted to make a brief comment about the
long-term natural history of this disease. Ten years ago, we had the
opportunity to publish a report on a series of 277 patients who
underwent operations at Baylor in the 1960s and 1970s before
composite grafts were prevalent (Lawrie GM, Earle N, DeBakey
ME. Long-term fate of the aortic root and aortic valve after
ascending aneurysm surgery. Ann Surg. 1993;217:711-20). We
ended up with a series of patients with simple tube grafts, with or
without a separate prosthetic aortic valve replacement. As a result,
we had 277 aortic roots and 118 native aortic valves that we were
able to follow for up to 40 years.
What we found was that simple tube graft replacement in the
patients without Marfan syndrome was a very reliable operation;
96% of the roots and their native valves came through 10 years
without any problem. On the other hand, the patients with Marfan
syndrome did not do so well. These patients had an 86% freedom
from reoperation for their root disease and only a 75% survival of
their Marfan valves, which were originally competent. This 25%
incidence of AI at 10 years is very similar to what Dr Tirone David
published last month for his patients undergoing valve-sparing
surgery (de Oliveira NC, David TE, Ivanov J, Armstrong S,
Eriksson MJ, Rakowski H, et al. Results of surgery for aortic root
aneurysm in patients with Marfan syndrome. J Thorac Cardiovasc
Surg. 2003;125:789-96).
Although this isn’t a direct parallel to your article, we did note
several points that would bear on your presentation. The first is that
most of these problems emerged in the 5- to 10-year time interval.
We had very few problems, almost no problems at all, in the 0- to
5-year interval. So I would continue to be cautious about the wide
application of this concept in Marfan syndrome. This is a real
problem. Again, 40 of 277 patients had Marfan syndrome, and
50% of the reoperations in the entire group were in those 40
patients.
I am glad to see you did pay attention to the incidence of
recurrent AI in great detail. I think we need to get back somewhat
parallel to the mitral repair situation in which we report the success
of our reconstructions according to the presence or absence of AI
rather than reoperation rates. AI is serious but sometimes well
tolerated for long periods of time, and I think we need to focus on
whether there is a competent valve or not.
Dr Karck. I agree. We have to wait until we have accumulated
much longer follow-up times. It is possible that beyond 5 years of
follow-up, complications will occur. So far, however, the results
are quite encouraging. Therefore, we will continue to offer this
operation to patients with Marfan syndrome too.
Surgery for Acquired Cardiovascular Disease Karck et al
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